Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tyrphostin AG 555 is a small molecule and potent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It displays high selectivity for EGFR over related kinases such as ErbB2 and insulin receptor kinase. The compound induces G1 cell cycle arrest selectively in transformed cells and has been shown to inhibit both early and late stages of viral replication cycles in certain retroviruses. It is primarily used as a research tool in laboratory settings to study EGFR signaling pathways and viral replication mechanisms[1][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tyrphostin ag 555.